IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 345,447 shares of the company’s stock after selling 1,649 shares during the period. Eagle Asset Management Inc. owned about 0.40% of IDEXX Laboratories worth $93,937,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IDXX. Altshuler Shaham Ltd acquired a new position in IDEXX Laboratories during the second quarter worth approximately $28,000. Usca Ria LLC acquired a new position in IDEXX Laboratories during the third quarter worth approximately $36,000. Cornerstone Advisors Inc. increased its position in IDEXX Laboratories by 100.0% during the second quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock worth $39,000 after purchasing an additional 70 shares during the last quarter. Captrust Financial Advisors increased its position in IDEXX Laboratories by 32.5% during the second quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock worth $42,000 after purchasing an additional 37 shares during the last quarter. Finally, Personal Wealth Partners acquired a new position in IDEXX Laboratories during the second quarter worth approximately $52,000. 86.85% of the stock is owned by institutional investors and hedge funds.

In other news, insider Jonathan W. Ayers sold 62,097 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $279.57, for a total value of $17,360,458.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,283 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $279.37, for a total transaction of $917,171.71. Following the completion of the sale, the director now directly owns 584 shares of the company’s stock, valued at approximately $163,152.08. The disclosure for this sale can be found here. Insiders sold 69,380 shares of company stock valued at $19,362,310 in the last three months. Company insiders own 2.70% of the company’s stock.

IDXX has been the subject of several research analyst reports. Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. Goldman Sachs Group initiated coverage on shares of IDEXX Laboratories in a research report on Monday, September 9th. They set a “neutral” rating and a $277.00 price target for the company. ValuEngine lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $285.00 price target on shares of IDEXX Laboratories in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. IDEXX Laboratories presently has an average rating of “Buy” and an average target price of $290.14.

Shares of IDEXX Laboratories stock traded down $8.40 during trading hours on Friday, hitting $254.74. The company’s stock had a trading volume of 772,200 shares, compared to its average volume of 445,642. IDEXX Laboratories, Inc. has a 1-year low of $176.11 and a 1-year high of $294.57. The business has a fifty day moving average of $273.75 and a 200 day moving average of $268.85. The company has a market capitalization of $22.66 billion, a PE ratio of 59.80 and a beta of 0.79. The company has a quick ratio of 0.80, a current ratio of 1.12 and a debt-to-equity ratio of 3.76.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.10. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The company had revenue of $605.30 million during the quarter, compared to analyst estimates of $597.09 million. During the same quarter in the prior year, the business earned $1.05 earnings per share. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 4.8 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: Should you buy a closed-end mutual fund?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply